A Multicenter, Single-arm, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacokinetics of CM310 in Children Subjects With Moderate-to-severe Atopic Dermatitis
Latest Information Update: 21 Oct 2024
At a glance
- Drugs Stapokibart (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- Sponsors KeyMed Biosciences
Most Recent Events
- 15 Oct 2024 Status changed from recruiting to completed.
- 11 Dec 2023 New trial record